Thymectomy for non-thymomatous myasthenia gravis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Cea, Gabriel ^a   Benatar, Michael ^b   Verdugo, Renato J ^c   Salinas, Rodrigo A ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

CLINICAL EFFECTIVENESS; HUMAN; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THYMECTOMY; THYMOMA;

HUMANS; MYASTHENIA GRAVIS; THYMECTOMY;

EID: 84899467576     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008111.pub2     Document Type: Review

References (82)

1. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. Journal of Neurology 1997;244(2):112-8.
2. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al.Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. Journal of the Neurological Sciences 1991;106(2):213-20.
3. Buckingham JM, Howard FM Jr, Bernatz PE, Payne WS, Harrison EG Jr, O'Brien PC, et al.The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Annals of Surgery 1976;184(4):453-8.
4. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40(5):786-90.
5. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. Journal of Neurology, Neurosurgery, and Psychiatry 1991;54(5):406-11.
6. Eaton LM, Clagett OT. Present status of thymectomy in treatment of myasthenia gravis. American Journal of Medicine 1955;19(5):703-17.
7. Edwards FR, Wilson A. Thymectomy for myasthenia gravis. Thorax 1972;27(5):513-6.
8. Emeryk B, Strugalska MH. Evaluation of results of thymectomy in myasthenia gravis. Journal of Neurology 1976;211(2):155-68.
9. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Annals of the New York Academy of Sciences 1987;505:472-99.
10. Henson RA, Stern GM, Thompson VC. Thymectomy for myasthenia gravis. Brain 1965;88:11-28.
11. Kawaguchi N, Kuwabara S, Nemoto Y, Fukutake T, Arimura K, Osame M, et al.Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clinical Neurology and Neurosurgery 2007;109(10):858-61.
12. Mack MJ, Landreneau RJ, Yim AP, Hazelrigg SR, Scruggs GR. Results of video-assisted thymectomy in patients with myasthenia gravis. Journal of Thoracic and Cardiovascular Surgery 1996;112(5):1352-9.
13. Manlulu A, Lee TW, Wan I, Law CY, Chang C, Garzon JC, et al.Video-assisted thoracic surgery thymectomy for nonthymomatous myasthenia gravis. Chest 2005;128(5):3454-60.
14. Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. Journal of Neurology 1990;237(6):339-44.
15. McQuillen MP, Leone MG. A treatment carol: thymectomy revisited. Neurology 1977;27(12):1103-6.
16. Tracy MM, McRae W, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. Journal of Child Neurology 2009;24(4):454-9.
17. Olanow CW, Wechsler AS, Sirotkin-Roses M, Stajich J, Roses AD. Thymectomy as primary therapy in myasthenia gravis. Annals of the New York Academy of Sciences 1987;505:595-606.
18. Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Annals of the New York Academy of Sciences 1981;377:678-90.
19. Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, Fagerstrom RP, Pozner J. Effects of thymectomy in myasthenia gravis. Annals of Surgery 1987;206(1):79-88.
20. Perlo VP, Arnason B, Poskanzer D, Castleman B, Schwab RS, Osserman KE, et al.The role of thymectomy in the treatment of myasthenia gravis. Annals of the New York Academy of Sciences 1971;183:308-15.
21. Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, et al.Thymectomy in the treatment of ocular myasthenia gravis. Journal of Thoracic and Cardiovascular Surgery 2001;122(3):562-8.
22. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Annals of Neurology 1983;13(5):504-10.
23. Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA. Thymectomy in nonthymoma early-onset myasthenia gravis in correlation with disease severity and muscle autoantibodies. European Neurology 2003;49(4):210-7.
24. Savcenko M, Wendt GK, Prince SL, Mack MJ. Video-assisted thymectomy for myasthenia gravis: an update of a single institution experience. European Journal of Cardiothoracic Surgery 2002;22(6):978-83.
25. Scadding GK, Havard CW, Lange MJ, Domb I. The long term experience of thymectomy for myasthenia gravis. Journal of Neurology, Neurosurgery, and Psychiatry 1985;48(5):401-6.
26. Simpson JA. An evaluation of thymectomy in myasthenia gravis. Brain 1958;81(1):112-44.
27. Soleimani A, Moayyeri A, Akhondzadeh S, Sadatsafavi M, Tavakoli Shalmani H, Soltanzadeh A. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. BMC Neurology 2004;4:12.
28. Téllez-Zenteno JF, Remes-Troche JM, García-Ramos G, Estañol B, Garduño-Espinoza J. Prognostic factors of thymectomy in patients with myasthenia gravis: a cohort of 132 patients. European Neurology 2001;46(4):171-7.
29. Werneck LC, Moreira PR. Myasthenia gravis: clinical and surgical treatment [Miatenia Grave: tratamiento clinico y cirurgico]. Arquivos de Neuro-psiquiatria 1991;49(4):409-17.
30. Yim AP, Kay RL, Ho JK. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest 1995;108(5):1440-3.
31. Zeldowicz LR, Saxton GD. Myasthenia gravis: comparative evaluation of medical and surgical treatment. Canadian Medical Association Journal 1969;101(10):88-93.
32. NCT00294658. A multi-center, single-blind, randomized study comparing thymectomy to no thymectomy in non-thymomatous myasthenia gravis (MG) patients receiving prednisone. http://clinicaltrials.gov/ct2/show/NCT00294658 (accessed April 7 2009).
33. Aarli JA. Late-onset myasthenia gravis: a changing scene. Archives of Neurology 1999;56(1):25-7.
34. Bedlack RS, Sanders DB. On the concept of myasthenic crisis. Journal of Clinical Neuromuscular Disease 2002;4(1):40-2.
35. Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Annals of Neurology 1983;14(5):516-9.
36. Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle and Nerve 2008;38(6):1553-62.
37. Buzzard EF. The clinical history and postmortem examination of five cases of myasthenia gravis. Brain 1905;28:438-83.
38. Casetta I, Groppo E, De Gennaro R, Cesnik E, Piccolo L, Volpato S, Granieri E. Myasthenia gravis: a changing pattern of incidence. Journal of Neurology 2010;257(12):2015-9.
39. Christensen PB, Jensen TS, Tsiropoulos I, Sørensen T, Kjaer M, Højer-Pedersen E, et al.Mortality and survival in myasthenia gravis: a Danish population based study. Journal of Neurology, Neurosurgery, and Psychiatry 1998;64(1):78-83.
40. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al.Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(Pt 10):2304-11.
41. French J, Gronseth G. Lost in a jungle of evidence: We need a compass. Neurology 2008;71(20):1634-8.
42. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002275]
43. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD002277.pub3]
44. Grimes DA, Schulz KF. An overview of clinical research: the lay of the land. Lancet 2002;359:57-61.
45. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(1):7-15.
46. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005224.pub2]
47. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Annals of Neurology 2011;69(2):418-22.
50. Hughes T. The early history of myasthenia gravis. Neuromuscular Disorders 2005;15(12):878-86.
51. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al.Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55(1):16-23.
52. Kaminski HJ. Myasthenia Gravis and Related Disorders. Totowa, NJ: Humana Press, 2003.
53. Kuks JB, Oosterhuis HJ, Limburg PC, The TH. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. Journal of Autoimmunity 1991;4(2):197-211.
54. Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990;40(12):1828-9.
55. Matsuda M, Dohi-Iijima N, Nakamura A, Sekijima Y, Morita H, Matsuzawa S, et al.Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan. Internal Medicine 2005;44(6):572-7. [PUBMED: 16020882]
56. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006986.pub2]
57. Melms A, Schalke BC, Kirchner T, Müller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. Journal of Clinical Investigation 1988;81(3):902-8.
58. Meriggioli M, Sanders D. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurology 2009;8(5):475-90.
59. Monden Y, Nakahara K, Kagotani K, Fujii Y, Masaoka A, Kawashima Y. Myasthenia gravis with thymoma: analysis of and postoperative prognosis for 65 patients with thymomatous myasthenia gravis. Annals of Thoracic Surgery 1984;38(1):46-52.
60. NCT00619671. Phase 1-2 pilot study of rituximab (Rituxan) in refractory myasthenia gravis. http://clinicaltrials.gov/ct2/show/NCT00619671 (accessed 18 March 2013).
61. NCT00774462. Rituximab for the treatment of refractory inflammatory myopathies and refractory myasthenia gravis. http://clinicaltrials.gov/ct2/show/NCT00774462 (accessed 18 March 2013).
62. Newsom-Davis J, Beeson D. Myasthenia gravis and myasthenic syndromes: autoimmune and genetic disorders. In: Karpati G, Hilton-Jones D, Griggs RC editor(s). Disorders of Voluntary Muscle. Cambridge: Cambridge University Press, 2001:660-75.
63. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52(10):1121-7.
64. Oosterhuis HJ. The ocular signs and symptoms of myasthenia gravis. Documenta Ophthalmologica 1982;52(3-4):363-78.
65. Palace J, Newsom-Davis J, Lecky B. A randomized double blind-trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50(6):1778-83.
66. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Annals of Neurology 1984;15(3):291-8.
67. Penn AS. Thymectomy for myasthenia gravis. In: Lisak RP editor(s). Handbook of Myasthenia Gravis and Myasthenic syndrome. New York: Marcel Dekker, 1994:321-39.
68. Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, et al.Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. Journal of Neurology 2012;259(3):427-35.
69. Phillips LH 2nd. The epidemiology of myasthenia gravis. Annals of the New York Academy of Sciences 2003;998:407-12.
70. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester (UK): John Wiley & Sons.
71. Riegelman RK. Database research: retrospective cohort studies. Studying a Study and Testing a Test: How to Read the Medical Evidence. 5th Edition. Philadelphia, PA: Wolters Kluwer, 2005:89-98.
72. Salomon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor α-subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. Journal of Clinical Investigation 1998;101(11):2340-50.
73. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Annals of Neurology 1987;22(2):212-22.
74. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002828.pub2]
75. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
76. Sonett JR, Jaretzki A 3rd. Thymectomy for nonthymomatous myasthenia gravis: a critical analysis. Annals of the New York Academy of Sciences 2008;1132:315-28.
77. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Annals of the New York Academy of Sciences 1993;681:539-51.
78. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357(9274):2122-8.
79. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nature Reviews Immunology 2002;2:797-804.
80. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical feature, antibodies and their targets. Lancet Neurology 2003;2:99-106.
81. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68(13):1051-7. [PUBMED: 17389311]
82. Cea G, Benatar M, Verdugo RJ, Salinas RA. Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008111]